Lupin to introduce Bepotastine tablets in India; Gets CDSCO approval
DSIJ Intelligence / 22 May 2017
Pharmaceutical company Lupin received approval for introducing the second-generation antihistamine tablets in India. Shortly, the pharma giant will start the promotion in India, informed the company in its BSE filing.
Pharmaceutical company Lupin received approval for introducing the second-generation antihistamine tablets in India from Central Drugs Standard Control Organisation (CDSCO). Shortly, the pharma giant will start the promotion in India, informed the company in its BSE filing.
Bepotastine is a new second generation antihistamine medicine to be introduced which benefit patients suffering from allergic symptoms and controls the day time and night time triggers of allergic symptoms.
Estimated current market is around Rs 860 crore growing at 14 per cent during March 2017 as per IMS MAT. Currently, it is actively marketed in Japan and other South East Asian countries.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.